
    
      This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent
      glioblastoma patients who were treated with standard concurrent chemoradiation.

      GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle)
      up to 6 cycles.
    
  